A fatal case of hidradenitis suppurativa associated with sepsis SCC after Infliximab (Remicade, Remsima, Inflectra) treatment

Screen Shot 2016-03-22 at 10.36.27 PM

With the patient’s agreement, we startedInfliximab (INN; trade names Remicade, Remsima, Inflectra) as an off-label treatment at a dosage of 0.5 mg/kg administered IV at 8-week intervals subsequent to the induction phase. After five months, the active lesions were found to have improved. At 10 months, the lesions were observed to have resolved, leaving persistent cicatricial scars and nodules, and the infliximab was discontinued. Three months later, the patient suddenly developed fever, arthromyalgia, and dyspnea, along with the reactivation of HS lesions, and was therefore hospitalized with a diagnosis of sepsis caused by Acinetobacter baumannii. Moreover, an ulcerative lesion developed on the upper right gluteus and enlarged to the size of 10 × 4 cm within five weeks. Histological examination of biopsy material obtained from the edge of the lesion showed a moderately differentiated squamous cell carcinoma (SCC).

Unfortunately, despite systemic antibiotic treatment (colistin IV), the patient died of complications caused by sepsis.

Source: A fatal case of hidradenitis suppurativa associated with sepsis and squamous cell carcinoma 


Leave a reply

HSAWARENESS.ORG | Fighting for Hidradenitis suppurativa (HS), a.k.a Acne Inversa Patient and Doctor Awareness ©2018 hidradenitissuppurativaawareness.org  All Rights Reserved. Your use of this website constitutes explicit agreement to our Terms of Use and Privacy Policies. This website does not provide medical advice, diagnosis or treatment.

Log in with your credentials

Forgot your details?